Our main goal is to provide a sustainable source of high purity grade new radionuclides for medicine, involving from the onset upcoming major European infrastructures, to provide a single-entry point for all researchers active in this field including SMEs, global pharma, nuclear centres, hospitals and universities, using standardised access procedures. The new isotope enrichment and standardisation techniques triggered in PRISMAP will expand our services and provide them to yet unreachable remote European laboratories. PRISMAP thus strives to create a paradigm shift in the early phase research on radiopharmaceuticals, targeted drugs for cancer – one of the major diseases in Europe – theranostics and personalised medicine, shaping the European isotope landmark as a gold standard to accelerate the development of the pharma industry and ultimately of a better healthcare for the improvement of our citizens’ life.
Our objectives are:
Notably, PRISMAP addresses cancer which is a major societal challenge as recently reconfirmed by Europe's Beating Cancer Plan.
The PRISMAP work plan consists of 13 work packages, including 3 transnational access activities, 5 networking activities, 4 enabling research activities and a work package dedicated to the project’s management.